一、中文名称：Research Grade Aflibercept (DHD12629),研究级Aflibercept生物类似药
二、产品描述
N2011年11月，美国FDA批准重组融合蛋白aflibercept作为玻璃体内注射，用于治疗新生血管性（湿性）年龄相关性黄斑变性（AMD）患者。afliberept与这些药物的不同之处在于，它作为一种可溶性诱饵受体，比其天然受体更紧密地结合所有VEGF亚型，从而转移VEGF的正常功能。Aflibercept由人VEGF受体1的第二Ig结构域和人VEGF受体2的第三Ig结构域融合到人免疫球蛋白G1 （Fc）的恒定区组成。afliberept是一种二聚体糖蛋白，蛋白分子量为97 kDa，糖苷分子量为18 kDa。它是在过表达融合蛋白的重组中国仓鼠卵巢（CHO）细胞中产生的。afliberept对VEGF-A具有亚皮摩尔亲和力（对VEGF-A165的KD=0.66 pM，对VEGF-A121的KD= 0.19 pM），这是湿性amd病理性血管生成和血管泄漏的主要驱动因素。雷尼单抗和贝伐单抗与VEGF-A165的亲和力较低（KD分别为20.6和35.1 pM）。
三、产品详情
名称：Research Grade Aflibercept (DHD12629)
别名：VEGF trap;Aflibercept1;VEGF Trap R1R2;Research Grade Aflibercept;Aflibercept iso-osmotic ophthalmic
货号：DHD12629
表达系统：Mammalian Cells
种属反应性：Human
宿主：Human
同种型：IgG1-Fc
克隆类型：Monoclonal
靶标：Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A
浓度：2.37 mg/ml
内毒素水平：Please contact with the lab for this information.
纯度：>95% as determined by SDS-PAGE.
纯化方式：Protein A/G purified from cell culture supernatant.
Accession号：P15692
克隆号：Aflibercept
应用：Research Grade Biosimilar
状态：Liquid
保存溶液：0.01M PBS, pH 7.4.
稳定性和存储：Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
四、参考文献：
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. PMID: 23084240
Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial. PMID: 35881122
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. PMID: 28837425
Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. PMID: 34351414
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. PMID: 26935357
Intravitreal Ziv-Aflibercept: A Comprehensive Review. PMID: 31314638
SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. PMID: 28106709
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. PMID: 37535382
INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial. PMID: 35234673
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. PMID: 22949147
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. PMID: 31037289
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. PMID: 29392288
Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications. PMID: 27166390
Aflibercept. PMID: 23444216
Aflibercept: A Review in Macular Oedema Secondary to Branch Retinal Vein Occlusion. PMID: 28365905
Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration. PMID: 30813810
Aflibercept: A Review in Metastatic Colorectal Cancer. PMID: 26220913
Up-to-date role of aflibercept in the treatment of colorectal cancer. PMID: 34085884
Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact. PMID: 28971631
Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option. PMID: 28548650
Aflibercept in the Treatment of Diabetic Macular Edema: A Review and Consensus Paper. PMID: 29077188
Intravitreal Brolucizumab and Aflibercept for Polypoidal Choroidal Vasculopathy. PMID: 37504966
Aflibercept: an update on recent milestones achieved. PMID: 25588083
Aflibercept for neovascular age-related macular degeneration. PMID: 26857947
Aflibercept (VEGF-TRAP): the next anti-VEGF drug. PMID: 21999177
Aflibercept a new target therapy in cancer treatment: a review. PMID: 26224565
Aflibercept for age-related macular degeneration: a game-changer or quiet addition? PMID: 22813448
Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer. PMID: 34986714
Aflibercept for intravitreal injection: in neovascular age-related macular degeneration. PMID: 23038609
Aflibercept suppresses ovarian hyperstimulation syndrome: an experimental study in rats. PMID: 37909622
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. PMID: 38461843
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. PMID: 30986442
Evaluation of aflibercept in the treatment of metastatic colorectal cancer. PMID: 25152076
A preclinical and clinical review of aflibercept for the management of cancer. PMID: 22264850
Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration. PMID: 23473589
Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. PMID: 27564719
Aflibercept for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis. PMID: 34908485
Aflibercept: newly approved for the treatment of macular edema following central retinal vein occlusion. PMID: 23673531
Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer. PMID: 24128964
Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration. PMID: 26076760
Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept. PMID: 37374329
详情请咨询Antibodysystem中国授权总代理-武汉佰乐博生物技术有限公司
网址：https://www.antibodysystem.com/product/658.html
武汉佰乐博生物技术有限公司作为法国Antibodysystem品牌亚洲区授权总代理。提供近3万种蛋白、抗体等核心生命科学试剂，旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。
试剂 | 耗材 | 定制 | 实验服务 | 供应链
免费热线：027-65279366 /18108604356
